PEGylation of Proteins: A Structural Approach - Structural properties of PEGylated proteins could play an increasingly important role in developing optimal therapeutic protein drugs. - BioPharm

ADVERTISEMENT

PEGylation of Proteins: A Structural Approach
Structural properties of PEGylated proteins could play an increasingly important role in developing optimal therapeutic protein drugs.


BioPharm International
Volume 19, Issue 4

21. Jeppesen C, et al. Impact of polymer tether length on multiple ligand-receptor bond formation. Science 2001, 293:465-68.

22. Fee CJ, Van Alstine JM, Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconj. Chem. 2004;15:1304-13.

23. Digilio G, et al. NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29) -NH2. J. Am. Chem, Soc. 2003;125:3458-70.

24. Greenwald RB. Poly(ethylene glycol) anticancer drug delivery systems. P. R. Health Sci. J. 2002, 21:113-121.

25. Hinds KD, Kim SW. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 2002;54:505-30.

26. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J. Pharm. Pharm. Sci. 2000, 3:125-136.

27. Lee KC, et al. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharm. Res. 1999, 16:813-18.

28. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 2001, 40:539-51.

29. Morpurgo M, et al. Preparation of characterization of poly(ethylene glycol) vinyl sulfone. Bioconjug. Chem. 1996, 7:363-68.

30. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 2002, 54:459-76.

31. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001, 22:405-17.

32. Wylie DC, et al. Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG. Pharm. Res. 2001, 18:1354-60.

33. Harris JM. Synthesis of polyethylene glycol derivatives. J. Macromol. Sci. Rev. Macromol. Chem. Phys. 1985, C25:325-73.

34. Wheelwright SM. Protein purification: design and scale up of downstream processing. New York: Whiley;1994.

35. Garcia-Arellano H, et al. High temperature biocatalysis by chemically modified cytochrome c. Bioconjug. Chem. 2002, 13:1336-44.

36. Eiteman MA, Hassinen C, Veide A. A mathematical model to predict the partitioning of peptides and peptide-modified proteins in aqueous two-phase systems. Biotechnol. Prog. 1994, 10:513-19.

37. Abbott NL, Blankschtein D, Hatton TA. Protein partitioning in two-phase aqueous polymer systems. A neutron scattering investigation of the polymer solution structure and protein-polymer interactions. Macromol. 1992, 25:3932-41.

38. Kerwin BA, et al. Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus. Protein Sci. 2002, 11:1825-33.

39. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1998, 1:352-56.

40. Roberts MJ, Harris JM. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. J. Pharm. Sci. 1998, 87:1440-45.

41. Campbell RM, et al. Pegylated peptides. V. Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo. J. Pept. Res. 1997, 49:527-37.

42. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv. Drug Deliv. Rev. 2002, 54:487-504.

43. Yamamoto Y, et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat. Biotechnol. 2003, 21:546-52.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines
Source: BioPharm International,
Click here